CellSource Co., Ltd.
Notice Regarding Revision of Earnings Guidance
Revised the full-year forecast for the fiscal year ending October 2026. Net sales to 3,367 million yen from 3,320 million yen; operating income to 82 million yen from -221 million yen; ordinary income to 76 million yen from -210 million yen; net income attributable to owners of parent to -124 million yen from -107 million yen, with earnings per share deteriorating from -5.41 yen to -6.26 yen. The main factor is expected non-operating losses related to the relocation of the headquarters. While contract processing services are expected to show higher sales, net income is expected to decline due to the impact of these special losses.
Key Figures
- Net sales: 3,367百万円（前回 3,320百万円）
- Operating income: 82百万円（前回 -221百万円）
- Ordinary income: 76百万円（前回 -210百万円）
- Net income attributable to owners of parent: -124百万円（前回 -107百万円）
- Earnings per share: -6.26円（前回 -5.41円）
AI要約
Overview of the Earnings Guidance Revision
The announced earnings forecast for the fiscal year ending October 2026 shows a modest increase in net sales from 3,320 million yen to 3,367 million yen, while operating income and ordinary income are expected to improve significantly; however, net income is projected to decline from -107 million yen to -124 million yen due to the recording of special losses related to the headquarters relocation. Details of the special losses can be found in the separately disclosed notice regarding the relocation of the headquarters and the recording of losses. While sales in the key area of contract processing services are expected to rise, overall net income is anticipated to decrease despite cost-cutting effects.
Impact of Headquarters Relocation and Outlook
The recording of special losses associated with the headquarters relocation is a downward pressure on the outlook for net income. Future performance will depend on trends in contract processing services and ongoing cost management. The assumptions at this time are based on publicly disclosed materials, and figures may be revised again depending on future factors.
CellSource Corporation
Company overview · Stock price · Financial data · All IR
